CoChat
Sign Up
Cited by 127

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives

Kuna, Lucija, Bozic, Ivana, Kizivat, Tomislav, Bojanic, Kristina, Mrso, Margareta, Kralj, Edgar, Smolic, Robert, Wu, George Y., Smolic, Martina·2018·Current Drug Metabolism
DOI 10.2174/1389200219666180523095355PMC PMC6174638
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1389200219666180523095355

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In pediatric medicine, DILI is rare but has high morbidity and mortality and is one of the most common causes of acute liver failure; diagnosis is challenging due to low incidence and phenotypic variability.

    “In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”

    From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [6]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 92

  1. [1]Hamilton L.A. Collins-Yoder A. Collins R.E. Drug-induced liver injury. AACN Adv. Crit. Care 2016 27 4 430 440 27959299
  2. [2]Vuppalanchi R. Liangpunsakul S. Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am. J. Gastroenterol. 2007 102 3 558 562 17156142
  3. [5]Ostapowicz G. Fontana R.J. Schiødt F.V. Larson A. Davern T.J. Han S.H. McCashland T.M. Shakil A.O. Hay J.E. Hynan L. Crippin J.S. Blei A.T. Samuel G. Reisch J. Lee W.M. U.S. Acute Liver Failure Study Group Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002 137 12 947 954 12484709
  4. [6]Halegoua-De Marzio D. Navarro V. Drug-induced hepatotoxicity in humans. Curr. Opin. Drug Discov. Devel. 2008 11 1 53 59 18175267
  5. [8]Chen M. Vijay V. Shi Q. Liu Z. Fang H. Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 2011 16 15-16 697 703 21624500
  6. [9]Almario E.E. Borlak J. Suzuki A. Chen M. Drug-induced liver injury. BioMed Res. Int. 2017 2017 2461694 28164116 PMC5253497
  7. [10]DeLeve L.D. Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000 60 3 143 154 10754451
  8. [11]Zimmerman H.J. Drug-induced liver disease. Clin. Liver Dis. 2000 4 1 73 96 11232192
  9. [12]DeLeve L.D. Wang X. Kuhlenkamp J.F. Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996 23 3 589 599 8617441
  10. [14]Hussaini S.H. Farrington E.A. Idiosyncratic drug-induced liver injury: An overview. Expert Opin. Drug Saf. 2007 6 6 673 684 17967156
  11. [15]Andrade R.J. Lucena M.I. Kaplowitz N. García-Muņoz B. Borraz Y. Pachkoria K. García-Cortés M. Fernández M.C. Pelaez G. Rodrigo L. Durán J.A. Costa J. Planas R. Barriocanal A. Guarner C. Romero-Gomez M. Muņoz-Yagüe T. Salmerón J. Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006 44 6 1581 1588 17133470
  12. [16]Björnsson E. Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005 42 2 481 489 16025496
  13. [17]Holt M. Ju C. Drug-induced liver injury. Handb. Exp. Pharmacol. 2010 196 3 27 20020257
  14. [18]Ulrich R. Idiosyncratic toxicity: A convergence of risk factors. Annu. Rev. Med. 2007 58 17 34 16958561
  15. [19]Han D. Shinohara M. Ybanez M.D. Saberi B. Kaplowitz N. Signal transduction pathways involved in drug-induced liver injury. Handb. Exp. Pharmacol. 2010 196 267 310 20020266
  16. [22]Daly A.K. Day C.P. Genetic association studies in drug-induced liver injury. Semin. Liver Dis. 2009 29 4 400 411 19826974
  17. [23]Hirata K. Takagi H. Yamamoto M. Matsumoto T. Nishiya T. Mori K. Shimizu S. Masumoto H. Okutani Y. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study. Pharmacogenomics J. 2008 8 1 29 33 17339877
  18. [24]Yuan L. Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J. Hepatol. 2015 7 28 2811 2818 26668692 PMC4670952
  19. [26]Zhang J. Doshi U. Suzuki A. Chang C.W. Borlak J. Li A.P. Tong W. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. Chem. Biol. Interact. 2016 255 3 11 26581450
  20. [27]Mann A. Pelz T. Rennert K. Mosig A. Decker M. Lupp A. Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance. Hum. Cell 2017 30 4 267 278 28527127
  21. [28]Donato M.T. Lahoz A. Castell J.V. Gómez-Lechón M.J. Cell lines: A tool for in vitro drug metabolism studies. Curr. Drug Metab. 2008 9 1 1 11 18220566
  22. [29]Castell J.V. Jover R. Martínez-Jiménez C.P. Gómez-Lechón M.J. Hepatocyte cell lines: Their use, scope and limitations in drug metabolism studies. Expert Opin. Drug Metab. Toxicol. 2006 2 2 183 212 16866607
  23. [30]Rodríguez-Antona C. Donato M.T. Boobis A. Edwards R.J. Watts P.S. Castell J.V. Gómez-Lechón M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: Molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002 32 6 505 520 12160483
  24. [31]Fischbach M. Cao H.W. Diez Ibanez M. Tsaconas C. Alouani S. Montandon F. El Baraka M. Padieu P. Dreano M. Chessebeuf-Padieu M. Maintenance of liver function in long term culture of hepatocytes following in vitro or in vivo Ha-rasEJ transfection. Cell Biol. Toxicol. 1991 7 4 327 345 1794108
  25. [32]Höhne M.W. Zieroth S. Veser U. Kahl G.F. Schwarz L.R. Carcinogen-induced diploid hepatocytes: sensitive target cells for transformation by mutated c-Ha-ras oncogene. Mol. Carcinog. 1993 7 3 180 189 8489713
  26. [33]Sirica A.E. Immortalizing hepatocytes with truncated MET: a little bit of gene goes a long way. Hepatology 1997 26 2 510 512 9252170
  27. [34]Donato M.T. Jover R. Gómez-Lechón M.J. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr. Drug Metab. 2013 14 9 946 968 24160292
  28. [35]Benet M. Lahoz A. Guzmán C. Castell J.V. Jover R. CCAAT/enhancer-binding protein alpha(C/EBPalpha) and hepatocyte nuclear factor 4alpha(HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6(CYP2B6) gene: application to the development of a metabolically competent human hepatic cell model. J. Biol. Chem. 2010 285 37 28457 28471 20622021 PMC2937871
  29. [36]Crespi C.L. Miller V.P. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol. Ther. 1999 84 2 121 131 10596902
  30. [37]Prakash C. Sharma R. Gleave M. Nedderman A. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr. Drug Metab. 2008 9 9 952 964 18991592
  31. [38]Sison-Young R.L. Kia R. Heslop J. Kelly L. Rowe C. Cross M.J. Kitteringham N.R. Hanley N. Park B.K. Goldring C.E. Human pluripotent stem cells for modeling toxicity. Adv. Pharmacol. 2012 63 207 256 22776643
  32. [39]Sirenko O. Hesley J. Rusyn I. Cromwell E.F. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev. Technol. 2014 12 1 43 54 24229356 PMC3934660
  33. [40]Kim J.H. Wang M. Lee J. Park H.J. Han C. Hong H.S. Kim J.S. An G.H. Park K. Park H.K. Zhu S.F. Sun X.B. Kim J.H. Woo D.H. Prediction of hepatotoxicity for drugs using human pluripotent stem cell-derived hepatocytes. Cell Biol. Toxicol. 2018 34 1 51 64 28382404
  34. [41]Anson B.D. Kolaja K.L. Kamp T.J. Opportunities for use of human iPS cells in predictive toxicology. Clin. Pharmacol. Ther. 2011 89 5 754 758 21430658 PMC3593635
  35. [42]Bale S.S. Vernetti L. Senutovitch N. Jindal R. Hegde M. Gough A. McCarty W.J. Bakan A. Bhushan A. Shun T.Y. Golberg I. DeBiasio R. Usta O.B. Taylor D.L. Yarmush M.L. In vitro platforms for evaluating liver toxicity. Exp. Biol. Med. (Maywood) 2014 239 9 1180 1191 24764241 PMC4156546
  36. [43]Holmgren G. Sjögren A.K. Barragan I. Sabirsh A. Sartipy P. Synnergren J. Björquist P. Ingelman-Sundberg M. Andersson T.B. Edsbagge J. Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. Drug Metab. Dispos. 2014 42 9 1401 1406 24980256
  37. [44]Takayama K. Morisaki Y. Kuno S. Nagamoto Y. Harada K. Furukawa N. Ohtaka M. Nishimura K. Imagawa K. Sakurai F. Tachibana M. Sumazaki R. Noguchi E. Nakanishi M. Hirata K. Kawabata K. Mizuguchi H. Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc. Natl. Acad. Sci. USA 2014 111 47 16772 16777 25385620 PMC4250156
  38. [45]Dash A. Inman W. Hoffmaster K. Sevidal S. Kelly J. Obach R.S. Griffith L.G. Tannenbaum S.R. Liver tissue engineering in the evaluation of drug safety. Expert Opin. Drug Metab. Toxicol. 2009 5 10 1159 1174 19637986 PMC4110978
  39. [46]Richert L. Binda D. Hamilton G. Viollon-Abadie C. Alexandre E. Bigot-Lasserre D. Bars R. Coassolo P. LeCluyse E. Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol. In Vitro 2002 16 1 89 99 11812644
  40. [47]Schyschka L. Sánchez J.J. Wang Z. Burkhardt B. Müller-Vieira U. Zeilinger K. Bachmann A. Nadalin S. Damm G. Nussler A.K. Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity. Arch. Toxicol. 2013 87 8 1581 1593 23728527
  41. [49]Andersson T.B. Evolution of novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Basic Clin. Pharmacol. Toxicol. 2017 121 4 234 238 28470941
  42. [50]Beckwitt C.H. Clark A.M. Wheeler S. Taylor D.L. Stolz D.B. Griffith L. Wells A. Liver ‘organ on a chip’. Exp. Cell Res. 2018 363 1 15 25 29291400 PMC5944300
  43. [52]Anders H.J. Vielhauer V. Identifying and validating novel targets with in vivo disease models: Guidelines for study design. Drug Discov. Today 2007 12 11-12 446 451 17532528
  44. [53]Morgan S.J. Elangbam C.S. Animal Models of Disease for Future Toxicity Predictions. New York John Wiley & Sons, Inc. 2016
  45. [54]Varga O. Hansen A. Sandoe P. Olsson I. Validating animal models for preclinical research: A scientific and ethical discussion. Altern. Lab. Anim. 2010 38 3 245 248 20602541
  46. [56]Ballet F. Hepatotoxicity in drug development: Detection, significance and solutions. J. Hepatol. 1997 26 26 36 9204407
  47. [58]Greaves P. Williams A. Eve M. First dose of potential new medicines to humans: How animals help. Nat. Rev. Drug Discov. 2004 3 3 226 236 15031736
  48. [60]Hasegawa M. Kawai K. Mitsui T. Taniguchi K. Monnai M. Wakui M. Ito M. Suematsu M. Peltz G. Nakamura M. Suemizu H. The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun. 2011 405 3 405 410 21238430 PMC3648850
  49. [61]Pridgeon S.C. Zhang F. Heslop J.A. Nugues C.M.L. Kitteringham N.R. Park B.K. Goldring C.E.P. Application of pluripotent stem cells in drug ‐ induced liver injury safety assessment. Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers. Will Y.J. McDuffie E. Jeffy B.D. Hoboken, New Jersey John Wiley & Sons, Inc. 2016 333
  50. [62]Madariaga M. Drug-related hepatotoxicity. N. Engl. J. Med. 2006 354 20 2192 2192 16710916
  51. [63]Dahlin D.C. Miwa G.T. Lu A.Y.H. Nelson S.D. N-acetyl-para-benzoquinone imine: A cytochrome-p-450-mediated oxidation-product of acetaminophen. Proc. Natl. Acad. Sci. USA 1984 81 5 1327 1331 6424115 PMC344826
  52. [64]Ng W. Lobach A.R. Zhu X. Chen X. Liu F. Metushi I.G. Sharma A. Li J. Cai P. Ip J. Novalen M. Popovic M. Zhang X. Tanino T. Nakagawa T. Li Y. Uetrecht J. Animal models of idiosyncratic drug reactions. Adv. Pharmacol. 2012 63 81 135 22776640
  53. [65]Roth R.A. Ganey P.E. Animal models of idiosyncratic drug-induced liver injury-current status. Crit. Rev. Toxicol. 2011 41 9 723 739 21726137
  54. [66]Metushi I.G. Hayes M.A. Uetrecht J. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 2015 61 4 1332 1342 25283142
  55. [67]Deng X. Luyendyk J.P. Ganey P.E. Roth R.A. Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models. Pharmacol. Rev. 2009 61 3 262 282 19805476 PMC2763781
  56. [68]Przybylak K.R. Cronin M.T. In silico models for drug-induced liver injury-current status. Expert Opin. Drug Metab. Toxicol. 2012 8 2 201 217 22248266
  57. [69]Chen M. Bisgin H. Tong L. Hong H. Fang H. Borlak J. Tong W. Toward predictive models for drug-induced liver injury in humans: Are we there yet? Biomarkers Med. 2014 8 2 201 213 24521015
  58. [70]Hewitt M. Enoch S.J. Madden J.C. Przybylak K.R. Cronin M.T. Hepatotoxicity: A scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action. Crit. Rev. Toxicol. 2013 43 7 537 558 23875763
  59. [71]Xu J.J. Diaz D. O’Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 2004 150 1 115 128 15522265
  60. [72]Tolosa L. Pinto S. Donato M.T. Lahoz A. Castell J.V. O’Connor J.E. Gómez-Lechón M.J. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol. Sci. 2012 127 1 187 198 22331495
  61. [73]Poulin P. Jones H.M. Jones R.D. Yates J.W. Gibson C.R. Chien J.Y. Ring B.J. Adkison K.K. He H. Vuppugalla R. Marathe P. Fischer V. Dutta S. Sinha V.K. Björnsson T. Lavé T. Ku M.S.PhR.M.A. CPCDC initiative on predictive models of human pharmacokinetics, part 1: Goals, properties of the PhRMA dataset, and comparison with literature datasets. J. Pharm. Sci. 2011 100 10 4050 4073 21523782
  62. [74]Uehara T. Ono A. Maruyama T. Kato I. Yamada H. Ohno Y. Urushidani T. The Japanese toxicogenomics project: Application of toxicogenomics. Mol. Nutr. Food Res. 2010 54 2 218 227 20041446
  63. [75]Ganter B. Snyder R.D. Halbert D.N. Lee M.D. Toxicogenomics in drug discovery and development: Mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. Pharmacogenomics 2006 7 7 1025 1044 17054413
  64. [76]Chen M. Zhang M. Borlak J. Tong W. A decade of toxicogenomic research and its contribution to toxicological science. Toxicol. Sci. 2012 130 2 217 228 22790972
  65. [77]Shenton J.M. Chen J. Uetrecht J.P. Animal models of idiosyncratic drug reactions. Chem. Biol. Interact. 2004 150 1 53 70 15522261
  66. [78]Ozer J. Ratner M. Shaw M. Bailey W. Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008 245 3 194 205 18291570
  67. [79]Ozer J.S. Chetty R. Kenna G. Palandra J. Zhang Y. Lanevschi A. Koppiker N. Souberbielle B.E. Ramaiah S.K. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul. Toxicol. Pharmacol. 2010 56 3 237 246 19903504
  68. [80]Ramaiah S.K. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem. Toxicol. 2007 45 9 1551 1557 17658209
  69. [81]Amacher D.E. Adler R. Herath A. Townsend R.R. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin. Chem. 2005 51 10 1796 1803 16099942
  70. [82]Schomaker S. Warner R. Bock J. Johnson K. Potter D. Van Winkle J. Aubrecht J. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol. Sci. 2013 132 2 276 283 23339181
  71. [84]Ding X. Ding J. Ning J. Yi F. Chen J. Zhao D. Zheng J. Liang Z. Hu Z. Du Q. Circulating microRNA-122 as a potential biomarker for liver injury. Mol. Med. Rep. 2012 5 6 1428 1432 22427142
  72. [85]Ward J. Kanchagar C. Veksler-Lublinsky I. Lee R.C. McGill M.R. Jaeschke H. Curry S.C. Ambros V.R. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc. Natl. Acad. Sci. USA 2014 111 33 12169 12174 25092309 PMC4143020
  73. [86]Krauskopf J. Caiment F. Claessen S.M. Johnson K.J. Warner R.L. Schomaker S.J. Burt D.A. Aubrecht J. Kleinjans J.C. Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol. Sci. 2015 143 2 268 276 25359176
  74. [87]Yang X. Salminen W.F. Shi Q. Greenhaw J. Gill P.S. Bhattacharyya S. Beger R.D. Mendrick D.L. Mattes W.B. James L.P. Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children. Toxicol. Appl. Pharmacol. 2015 284 2 180 187 25708609 PMC4558622
  75. [88]McGill M.R. Jaeschke H. MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury. J. Clin. Med. 2015 4 5 1063 1078 26167291 PMC4470217
  76. [89]Antoine D.J. Dear J.W. Lewis P.S. Platt V. Coyle J. Masson M. Thanacoody R.H. Gray A.J. Webb D.J. Moggs J.G. Bateman D.N. Goldring C.E. Park B.K. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013 58 2 777 787 23390034 PMC3842113
  77. [90]Yang X. Greenhaw J. Shi Q. Su Z. Qian F. Davis K. Mendrick D.L. Salminen W.F. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol. Sci. 2012 125 2 335 344 22112502
  78. [92]Sanjay S. Girish C. Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury. Eur. J. Clin. Pharmacol. 2017 73 4 399 407 28028586
  79. [93]Laverty H.G. Antoine D.J. Benson C. Chaponda M. Williams D. Kevin Park B. The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur. J. Clin. Pharmacol. 2010 66 10 961 976 20694460
  80. [94]Tarrant J.M. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: Considerations for their use. Toxicol. Sci. 2010 117 1 4 16 20447938 PMC2923281
  81. [95]Van Ravenzwaay B. Cunha G.C. Leibold E. Looser R. Mellert W. Prokoudine A. Walk T. Wiemer J. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol. Lett. 2007 172 1-2 21 28 17614222
  82. [96]Goodsaid F.M. Frueh F.W. Mattes W. Strategic paths for biomarker qualification. Toxicology 2008 245 3 219 223 18280028
  83. [97]Pirmohamed M. Genetics and the potential for predictive tests in adverse drug reactions. Chem. Immunol. Allergy 2012 97 18 31 22613851
  84. [98]Clare K.E. Miller M.H. Dillon J.F. Genetic factors influencing drug-induced liver injury: Do they have a role in prevention and diagnosis? Curr. Hepatol. Rep. 2017 16 3 258 264 28856081 PMC5556130
  85. [99]O’Donohue J. Oien K.A. Donaldson P. Underhill J. Clare M. MacSween R.N. Mills P.R. Co-amoxiclav jaundice: Clinical and histological features and HLA class II association. Gut 2000 47 5 717 720 11034591 PMC1728095
  86. [100]Grove J.I. Aithal G.P. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert Opin. Drug Metab. Toxicol. 2015 11 3 395 409 25491399
  87. [101]Aithal G.P. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: Current role in clinical practice. Liver Int. 2015 35 7 1801 1808 25809692
  88. [102]Cai Y. Yi J. Zhou C. Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 2012 7 10 e47769 23082213 PMC3474796
  89. [103]Urban T.J. Daly A.K. Aithal G.P. Genetic basis of drug-induced liver injury: Present and future. Semin. Liver Dis. 2014 34 2 123 133 24879978
  90. [104]Aithal G.P. Day C.P. Leathart J.B. Daly A.K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000 10 6 511 518 10975605
  91. [105]Karlin E. Phillips E. Genotyping for severe drug hypersensitivity. Curr. Allergy Asthma Rep. 2014 14 3 418 24429903 PMC4014135
  92. [106]Kaniwa N. Saito Y. Pharmacogenomics of severe cutaneous adverse reactions. Pharmacogenomics 2013 14 6 595 598 23570461

Cited by

Sorted by citations

Metadata

Authors
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M.
Affiliations
  • Department of Chemistry and Biochemistry, Faculty of Dental Medicine and Health, J. J. Strossmayer University of Osijek, Crkvena 21, 31000 Osijek, Croatia
  • Department of Pharmacology, Faculty of Medicine, J. J. Strossmayer University of Osijek, J. Huttlera 4, 31000 Osijek, Croatia
  • Inspecto, LLC, Martina Divalta 193, 31000 Osijek, Croatia
  • Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, United States
Venue
Current Drug Metabolism
Publisher
Bentham Science Publishers Ltd.
Published
2018-09-14
Volume
19
Issue
10
Pages
830-838
ISSN
1389-2002
DOI
10.2174/1389200219666180523095355
PMC
PMC6174638
Cited by
127
References
10
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review